Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation
A phase 3 trial of Abemaciclib and Fulvestrant in advanced solid tumours, run by LeonaBio, now recruiting.
Overview
Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation is a phase 3 interventional study registered as NCT05696626 by LeonaBio, with 600 participants planned, started 2023-10-31 and due to reach its primary completion in 2027-04. Interventions recorded: Lasofoxifene in combination with abemaciclib and Fulvestrant in combination with abemaciclib.
Similar pages
not linked directly; found by shared links- TrialA Study of Abemaciclib (LY2835219) in Participants With Breast Cancer
Shares Abemaciclib, Fulvestrant, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialPhase 1/1b/2 Study of Oral PMD-026 in Patients With Metastatic Breast Cancer
Shares Fulvestrant, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialPhase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors
Shares Fulvestrant, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA Study of Abemaciclib (LY2835219) Combined With Fulvestrant in Women With Hormone Receptor Positive HER2 Negative Breast Cancer
Shares Abemaciclib, Fulvestrant and the tag pipeline.
- TrialSNV4818 in Participants With Advanced Solid Tumors
Shares Fulvestrant, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialPhase Ib/II Clinical Study of QLS1304 Combined With Endocrine Therapy in the Treatment of ER+/HER2- Breast Cancer Patients
Shares Fulvestrant, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialCapivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292)
Shares Abemaciclib, Fulvestrant, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialCapivasertib+Fulvestrant asTreatment for Locally Advanced(Inoperable) or Metastatic HR+/HER2- Breast Cancer in Chinese Patients
Shares Fulvestrant, Metastatic cancer (cancer that has spread) and the tag pipeline.